CTOs on the Move

Respicardia

www.respicardia.com

 
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē® System is an innovative implantable stimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.respicardia.com
  • 12400 Whitewater Dr Suite 150
    Minnetonka, MN USA 55343
  • Phone: 952.540.4470

Executives

Name Title Contact Details

Funding

Respicardia raised $58.5M on 12/19/2017

Similar Companies

Marketlab

MarketLab is committed to keeping our customers informed. We periodically send out newsletters on a variety of topics. If you are interested in hearing from us just sign up.

Rafi Systems Inc

Rafi Systems Inc is a Diamond Bar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jj Medical System

Jj Medical System Llc is a Bingham Farms, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Palomar Medical Technologies

Palomar Medical Technologies, Inc. is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Smith and Nephew

Smith & Nephew is a global advanced medical technology business. We support healthcare professionals in more than 100 countries to improve the quality of life for their patients. Since 1856, when our founder T.J. Smith developed a new method for refining cod liver oil, and in World War One when his nephew led the supply of wound care products, to the present day, Smith & Nephew continues to pioneer health solutions. Through our market leadership positions in Sports Medicine, Trauma, Orthopaedic Reconstruction and Advanced Wound Management, our 16,000 employees continue to improve outcomes and expand access, constantly striving to create value for healthcare professionals, patients, payers and shareholders. Annual sales in 2016 were more than $4.6 billion. We are a constituent of the UK’s FTSE100 and our shares are traded on London Stock Exchange and through American Depository Receipts on the New York Stock Exchange   We have leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma.   We have almost 11,000 employees and a presence in more than 90 countries.   Annual sales in 2013 were more than $4.3 billion.   We are a constituent of the UK's FTSE100 and our shares are traded on the London Stock Exchange and through American Depository Receipts on the New York Stock Exchange (LSE: SN, NYSE: SNN)